ClinConnect ClinConnect Logo
Search / Trial NCT06073223

Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer

Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · Oct 3, 2023

Trial Information

Current as of September 10, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying ways to help patients with low-risk thyroid cancer make informed treatment decisions and avoid unnecessary treatments. It includes 50 participants, aged 18 to 80, who have been newly diagnosed with low-risk papillary thyroid cancer. To be eligible, patients need to have a specific type of thyroid tumor that is small, has not spread to lymph nodes or other parts of the body, and must be referred for surgery. Participants will be randomly divided into two groups: one will receive additional information and support to help them understand their treatment options, while the other group will receive standard care, which includes information only during their surgeon visit.

Participants can expect to take part in surveys about their treatment choices and understanding of their condition, both before and after meeting with their surgeon. The goal is to see if the extra support helps patients make better choices about their treatment. It's important to know that this study is currently recruiting participants, and it aims to improve the decision-making process for those diagnosed with low-risk thyroid cancer.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 to 80 years
  • Low risk papillary thyroid cancer or highly suspicious for cancer
  • Low risk papillary thyroid cancer
  • cT1-2: Tumor size 4 cm or smaller and limited to the thyroid on ultrasound
  • cN0: No evidence of lymph node metastasis on ultrasound
  • cM0: No evidence of distant metastasis on imaging
  • Highly suspicious for cancer
  • Cytology meeting Bethesda V or Bethesday III or IV with molecular testing indicating a 70% risk of greater of thyroid cancer
  • Nodule size 4 cm and smaller
  • Limited to the thyroid on ultrasound
  • No evidence of suspicious lymph nodes
  • No evidence of thyroid cancer outside of the neck
  • Referred for surgical consultation.
  • Exclusion Criteria:
  • History of previous thyroid cancer or thyroid surgery and parathyroid surgery
  • Non-English speaking
  • Deaf
  • Subject Selection (for Surgeons)
  • Surgeon Inclusion Criteria
  • Performs at least one thyroid surgery annually on adults
  • Credentialed at Michigan Medicine
  • Surgeon Exclusion Criteria
  • None

About University Of Michigan Rogel Cancer Center

The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.

Locations

Ann Arbor, Michigan, United States

Patients applied

0 patients applied

Trial Officials

Susan Pitt

Principal Investigator

University of Michigan Rogel Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported